Alfacell Corporation

Pharmaceutical firm reports $0.06 per share loss, clinical pipeline update

Published in Lab Business Week, April 17th, 2005

Alfacell Corporation (ACEL) announced its financial results for the second quarter of its 2005 fiscal year, reflecting continued investments in the company's clinical and preclinical programs.

Research and development expenses for the second quarter of FY2005 totaled $1.6 million as compared to $.7 million for the second quarter of FY2004. The increase in R&D expenses reflects an expansion in the company's Onconase phase IIIb clinical trial for malignant mesothelioma, primarily in Europe, Australia and New Zealand.

The company also incurred higher data management and clinical trial monitoring fees related to the phase IIIb trial as well as expenses...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Lab Business Week

Source: Lab Business Week (2005-04-17)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry